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ABSTRACT   Recurrent proctitis and the symptoms associated therewith pose significant clinical problem in proctological patients. 
  The objective of this study was to assess the impact of the probiotic Lactobacillus rhamnosus PL1 strain on the clinical pres-
entation and composition of intestinal microbiota in patients with symptoms of proctitis in the course of hemorrhoidal 
disease and diverticulosis. 
  Material consisted of 24 patients in whom no complete clinical improvement could be obtained after the treatment of the 
underlying disease. Subject to the assessment was the presence and the intensity of clinical symptoms as well as qualita-
tive and quantitative changes in the composition of bacterial flora detected in the stool before, during and after a 9-week 
supplementation with the probiotic Lactobacillus rhamnosus PL1 strain. 
  Results: In the entire study group, the intensity of pain after 12 weeks was significantly lower (p=0.011) compared to baseline; the 
intensity of flatulence and abdominal discomfort was reduced significantly as early as after 3 weeks, with the difference reach-
ing a highly significant level after 12 weeks (P<0.0001). No significant difference was observed in the frequency of the reported 
episodes of diarrhea, constipation, as well as itching and burning in the anal region. As early as after 3 weeks of supplementation 
with the probiotic L. rhamnosus PL1 strain, significant qualitative and quantitative changes were observed in the composition of 
intestinal microbiota; the changes differed depending on the underlying disease. An increase in the total counts of the bacteria 
of Lactobacillus genus, particularly L. rhamnosus PL1 strain was observed regardless of the underlying disease. 
  Conclusion: the probiotic Lactobacillus rhamnosus PL1 strain appears to be useful in restoring appropriate ratios of bacterial 
populations in patients presenting with symptoms of proctitis in the course of the treatment of certain diseases of the low-
er gastrointestinal tract.
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INTRODUCTION
In proctological practice one may encounter a significant number of 
patients who suffer from recurrent proctitis and symptoms associ-
ated therewith despite having undergone the frequently successful 
treatment for the underlying disease of the lower gastrointestinal tract 
(hemorrhoidal disease, anal fissure, perianal fistula, diverticulosis). Pa-
tients presenting with symptoms of moderately intense inflammation 
in anoscopic examination and lack of other abnormalities in labora-
tory, endoscopic and imaging studies main complain of pain within 
the lower abdomen and the anal region, abdominal discomfort, flatu-
lence, constipation, sudden bowel movements, feeling of incomplete 
voiding as well as itching and burning in the anal region. The change 
in nutritional habits and the use of elimination diets are insufficient 
to bring about the expected results. The possibility that the symptoms 
may be due to the disturbance in composition of gut microbiota is 
usually considered as the last option. Even so, physicians are reluctant 
in prescribing probiotics as they assume that supplementation with 
a single bacterial strain, sometimes of dubious activity, is insufficient 
to dramatically change the composition of gut microbiota and con-
sequently the clinical presentation of the disease.
Appropriate ratios of bacterial populations within the gut microbiota 
have long been known to be a condition required for the proper func-
tion of the large intestine and the entire immune system. The compo-
sition of gut microbiota is determined by numerous factors such as 
the age (1), nutritional habits, chronic diseases, or the need for treat-
ment using antibiotics or steroidal anti-inflammatory drugs. Signifi-
cant shifts in the ecological equilibrium of intestinal microflora may 
also occur over short time due to the inflammatory processes within 
the intestinal lumen involving the release of reactive oxygen species 
(ROS) and inflammatory mediators or bleeding within the intestinal 
tract. The disturbance of this sensitive microbial equilibrium results 
in the maintenance of inflammation within the large intestinal mucosa 
and consequently to the increase in clinical symptoms. 
Every year provides new scientific evidence to support the claim 
that dysbiosis, i.e. disturbed composition of gut microbiota plays 
an important role in the pathogenesis or is a consequence of both 
intestinal (inflammatory bowel disease, irritable bowel syndrome, 
diverticulosis, celiac disease) as well as extraintestinal (allergies, 
asthma, metabolic syndrome, cardiovascular diseases) systemic 
disorders (2) and cancers.
Appreciating the value of the proper composition of gut microflo-
ra, the authors made an attempt at verification whether and how 
supplementation using a single probiotic bacterial strain affect-
ed the clinical presentation of the disease and the gut microbiota 
composition in proctological patients presenting with symptoms 
of proctitis.
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Microbiological analysis of stool samples
Stool samples were collected from each patient at visits V1 and V2. 
Stool was collected from rectal ampulla about 7cm above the sphinc-
ter muscles using an anoscope. Following collection, samples were 
immersed in Schaedler broth with the addition of 15% of glycerol in 
sterile 50 mL tubes and immediately frozen at -20⁰C. The material 
was transported to the microbiological lab in dry ice for deep freez-
ing. Before culturing, the samples were thawed at room tempera-
ture and blended using a stomacher (Bagmixer 400 P, Bionovo). The 
material was inoculated in 100 µL aliquots onto appropriate solid 
growth media, including McConkey agar for Gram-negative bacil-
li, Columbia agar for and streptococci and staphylococci, Schaedler 
agar for anaerobic bacteria, and MRS for lactic acid bacteria of genus 
Lactobacillus. Sabourand agar was used for confirming the presence 
of Candida fungi in the study material. The inoculated material was 
placed in a heater set at 37⁰C in aerobic or anaerobic conditions for 
24 or 48 hours, respectively. The cultured colonies were identified in 
terms of genus and species using bioMerieux API kits (API 20E, API 
20A, API Strep, API Staph, API 50CH) and subsequently quantified. 
Final results were expressed as culture forming units per one gram 
of stool (CFU/g of stool). Only in the case of lactic acid bacteria pre-
liminarily identified using the phenotyping method (API 50 CHL) 
as L. rhamnosus, further identification was performed using a geno-
typing method, namely PCR with species-specific primers (PrI: CAG 
ACT GAA AGT CTG ACG G, RhaII: GCG ATG CGA ATT TCT 
ATT ATT ) (3). Pulsed-field gel electrophoresis (PFGE) was used in 
order to decisively confirm the colonization of gastrointestinal tracts 
of the study patients with the probiotic L. rhamnosus PL1 strain. The 
technique allows to compare the genomic DNA profiles of all bacte-
ria identified as L. rhamnosus to the reference profile typical for the 
PL1 strain. Isolation of genomic DNA and selection of restriction en-
zymes was based on the methodology proposed by Tynkkynen (4).
Statistical analysis
The collected results were processed and entered into excel spread-
sheets (raw data). The raw data were subjected to statistical anal-
ysis (Student’s t-test, chi-square test and Mann-Whitney’s U-test; 
the latter two tests were used as non-parametric tests to estimate 
the errors of measurement) to demonstrate the changes between 
the baseline and the end of study (endpoint analysis) as well as 
between the baseline and follow-up visits (interim analysis). Pri-
mary endpoints were defined as the presence (assessed as 0 or 1) 
and the changes in the intensity of clinical symptoms (assessed 
on the scale from 0 to 5) Secondary endpoints were defined as 
qualitative and quantitative changes in the composition of bacte-
rial species present in stool samples, including the bacteria of the 
family Enterobacteriaceae, bacilli of Escherichia coli, enterococci 
and Enterococcus faecalis strains. Changes in the quantitative ra-
tios between the counts of aerobic bacteria and strictly anaerobic 
bacteria were also analyzed. Additional attention was paid to the 
quantitative changes observed between stool samples collected at 
visits V1 and V2 with reference to the total count of Lactobacil-
lus genus, particularly of the probiotic L. rhamnosus PL1 strain. 
RESULTS
The study group of 24 patients (13 women and 11 men) included 
17 patients with hemorrhoidal disease and 7 patient with diver-
The objective of this study was to assess the impact of the pro-
biotic Lactobacillus rhamnosus PL1 strain on the clinical pres-
entation and composition of intestinal microbiota in patients 
with symptoms of proctitis in the course of hemorrhoidal dis-
ease and diverticulosis.
MATERIAL AND METHOD
Patients
Included in the analysis were a total of 24 patients, including 17 
patients with hemorrhoidal disease and 7 patients with divertic-
ulosis treated at the Outpatient Clinic of the Department of Gen-
eral, Oncological and Gastrointestinal Surgery with no complete 
clinical improvement following the treatment of the underlying 
disease. Qualified for the study were:
• Patients with grade II and III hemorrhoidal disease after 
conservative and/or surgical treatment and presenting with 
symptoms of rectal mucositis in anoscopic examination, 
with the history of earlier standardized, 8-week 
conservative treatment (ointments and suppositories), 
improvement in follow-up anoscopic examination, and 
persisting complaints; and 
• Patients with endoscopically confirmed diverticulosis, 
currently without features of acute diverticulitis, who had 
completed the standard treatment with rifaximin for 6 
months (2x2 tablets for 7 days repeated every 1 month) and 
nonetheless presented with persistent features of proctitis 
in anoscopic examination and symptoms within the lower 
gastrointestinal tract.
All patients were included in the study after at least 4 weeks of 
washout with regard to all antibiotic medications or probiotic 
products.
The observation time in this prospective, self-controlled study 
was 12 weeks. Baseline evaluations included the presence and 
intensity of clinical symptoms, proctological examination (with 
anoscopic assessment), laboratory analyses (hematology, CRP), 
and standardized collection of a stool sample (SS1) from the rec-
tal ampulla for determination of baseline gut microbiotic status. 
The presence of clinical symptoms of gas and stool incontinence 
was assessed by means of Wexner scale. Following the baseline 
assessments, each patient received the probiotic product conta-
ining the single Lactobacillus rhamnosus PL1 strain for regular 
use 1 time daily for 9 weeks. The presence (assessed as 0 or 1) 
and the changes in the intensity of clinical symptoms (assessed 
on the scale from 0 to 5) was recorded throughout the study in 
the patient diary. Follow-up visits were held during the observa-
tion period, including V2 after 3 weeks, V3 after 6 weeks, and V4 
after 12 weeks from the start of probiotic treatment. Stool sam-
ples were collected for microbiological analyses during the first 
visit (SS1) as well as during the second visit (SS2) i.e. after 3 we-
eks of probiotic treatment. The microbiological analyses of the 
stool sample were quantitative determinations focusing on the 
changes in the counts of bacterial strains comprising the gut mi-
crobiota and on the efficacy of gut colonization by the probiotic 
L. rhamnosus PL1 strain. In addition, the presence and changes 
in the intensity of clinical symptoms were assessed at V3 (after 
6 weeks) and V4 (after 12 weeks).
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terobacteriaceae (p<0.0001), including E. coli (p<0,0001), and cocci 
of genus Enterococcus (p<0.0001), (Figure 3A).  
In patients with diverticulosis, the quantitative ratio between aerobic 
and anaerobic bacterial counts differed significantly from those ob-
served in patients with hemorrhoidal disease. After 3 weeks of supple-
mentation, a significant increase in the total aerobic bacterial counts 
was observed (p=0.0001) (Figure 2B). This increase was due to the 
increase in the population of Gram-negative bacilli of genus Entero-
bacteriaceae (p=0.0001) but not to the increase in the population of 
cocci of the family Enterococcus, since the latter, also classified as aer-
obic bacteria, showed a decreasing trend at V2 (p=0.0001) (Figure 3B). 
ticulosis. The mean age of patients was 51.7 years. The character-
istics of both groups is provided in Table 1.
Changes in the intensity of the clinical symptoms were observed 
in the course of the study after 3, 6, and 12 weeks. The intensity of 
pain after 12 weeks was significantly lower (p=0.011) as compared 
to baseline. The intensity of flatulence decreased significantly after 
3 weeks; in a longer observation period (12 weeks), the difference 
reached a highly significant level (p=0.0002). Abdominal discomfort 
was reduced starting from the early observation stage (significant 
difference achieved as early as after 3 weeks),reaching a highly signi-
ficant level (p<0.0001) after 12 weeks. See Table 2 for details. Baseli-
ne itching and burning in the anal region was reported by 33.3% as 
compared to 12.5% after 12 weeks; the difference, however, was not 
statistically significant (p=0.49). Identical results were obtained for 
diarrhea (33.3% before vs. 12.5% after 12 weeks from the start of the 
treatment, p=0.49). Baseline constipation was reported by 58.33% 
(14/24) of patients; after 3 weeks, the percentage dropped to 12.5% 
(3/24) and after 12 weeks from the start of the treatment (3 weeks 
after discontinuation of the probiotic product) the problem was not 
reported by any of the patients (p<0.0001).
In a detailed analysis of the group of 17 patients with hemorrho-
idal disease, particular differences were observed in the intensi-
ty of flatulence (p=0.005) and abdominal discomfort (p=0,002) 
which were significantly reduced. The difference in the intensity 
of sudden bowel movements was not statistically significant (Ta-
ble 3). No significant difference was observed in the reported rates 
of diarrhea (6/17 vs. 2/17, p=0.556), constipation (5/17 vs. 0/17, 
p=0.097), as well as itching and burning in the anal region (6/17 
vs. 3/17, p=0.789).
In the group of patients with diverticulosis, the most evident chan-
ges included the reduction in the intensity of pain (p=0.025), fla-
tulence (p=0.029) and abdominal discomfort (p=0.005) after 12 
weeks (Table 4). No differences were observed with regard to the 
rates of itching in the anal region, diarrhea (2/7 vs. 1/7, p=0.836) 
and constipation (2/7 vs. 0/7, p=0.056).
Results of microbiological analyses 
Three weeks of oral supplementation using a single probiotic strain 
L. rhamnosus PL1 resulted in significant changes in the composi-
tion of gut microbiota. A significant reduction in the population 
of aerobic bacteria (p<0.0001) was observed in patients with hem-
orrhoidal disease while the strictly anaerobic bacterial counts re-
mained unchanged (Figure 2A). The aforementioned drop (observed 
at the second visit) was associated with the statistically significant 
reduction in the counts of Gram-negative bacilli of the family En-
Tab. I. Characteristics of the study groups
 PATIENTS WITH 
HEMORRHOIDAL 
DISEASE
PATIENTS WITH 
DIVERTICULOSIS
TOTAL NUMBER OF STUDY 
PATIENTS
N 17 7 24
Women 41.2% (7) 85.7% (6) 54.2% (13)
Men 58.8% (10) 14.3% (1) 45.8% (11)
Mean age 43.5 70.4 51.7
Duration of 
symptoms 
(months)
36.5 28.7 34.2
Conservative 
treatment
100% (17/17) 100% (7/7) 100% (24/24) 
Surgical 
treatment
70.6% (12/17) 14.3% (1/7) 54.2% (13/24)
Wexner scale 
score
0.5 2 0.96
CRP 4.07 6.9 4.88
Tab. II.  Intensity of clinical symptoms within the study group at individual time points 
(mean ± SEM)
V1 V2 V4 P
Abdominal pain 1.78 ± 0.28 1.33 ± 0.27 0.58 ± 0.19 0.01
Flatulence 2.69 ± 0.27 1.47 ± 0.29 1.0 ± 0.22 0.0002
Abdominal 
discomfort
2.69 ± 0.31 1.47 ± 0.23 0.76 ± 0.25 <0.0001
Sudden bowel 
movements
2.00 ± 0.4 1.09 ± 0.38 0.53 ± 0.32 0.029
Tab. III.  Intensity of clinical symptoms in patients with hemorrhoidal disease (mean ± SEM)
V1 V2 V4 P
Abdominal pain 1.56 ± 0.36 1.46 ± 0.35 0.45 ± 0.24 0.074
Flatulence 2.81 ± 0.35 1.6 ± 0.38 1.00 ± 0.33 0.005
Abdominal 
discomfort
2.62 ± 0.41 1.4 ± 0.32 0.63 ± 0.33 0.002
Sudden bowel 
movements
2.56 ± 0.48 1.53 ± 0.49 0.81 ± 0.48 0.059
Fig. 1. Study design 
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fort and pain. This was not surprising considering the underlying 
disease. Disturbed composition of gut microbiota is considered 
to be the key factor responsible for exacerbations in the course 
The reduction in the total population of fecal cocci of the family 
Enterococcus as observed at the second visit (V2) may be directly 
associated with the improvement of clinical parameters observed 
as early as after 3 weeks of probiotic treatment (Table 4). 
No bacteria of genus Lactobacillus were found in the baseline 
stool sample (SS1) in 7 out of 17 patients (41.18%) treated for 
hemorrhoidal disease. After 3 weeks of oral supplementation, 
bacteria of this genus were found in 15 out of 17 patients (88.24%) 
(Table 5). Colonization by L. rhamnosus PL1 strain was confirmed 
in 15 out of 17 patients treated for hemorrhoidal disease which 
amounts to colonization efficacy rate of 88.24% (Figure 4). 
In case of patients treated for diverticulosis, colonization of the 
gastrointestinal tract with the L.rhamnosus PL1 strain after 3 weeks 
of supplementation was confirmed in 4 cases (57% of patients). With 
regard to the impact of the L. rhamnosus PL1 strain on the increase 
on the total counts of the bacteria of genus Lactobacillus, it was even 
more evident than in patients with hemorrhoidal disease (Table 6). 
Namely, only 1 in 7 patients included in the study presented with 
Lactobacillus colonization at V1 (14 %) while the number of patients 
with Lactobacillus colonization at V2 increased to 6 out of 7 patients 
(86%).
DISCUSSION
Improvement in the intensity of clinical symptoms was observed in 
the during the study in the entire patient population. After 9 weeks 
of supplementation using a single probiotic Lactobacillus rhamnosus 
PL1 strain, a statistically significant decrease was observed in the fre-
quency of pain, flatulence, abdominal discomfort and constipation as 
reported by patients. The change in clinical presentation was depend-
ent on the underlying disease. In patients treated for hemorrhoidal 
disease, the improvement was observed mainly in the intensity of 
flatulence and abdominal discomfort. Despite the lack of statistical 
significance, improvement was observed in some patients with regard 
to the intensity of sudden bowel movements and diarrhea (4 out of 
6 patients who reported the problem at baseline), constipation (all 
5 patients who reported the problem at baseline), as well as itching 
and burning in the anal region (3 out of 6 patients who reported the 
problem at baseline). The few available literature reports on the sub-
ject confirm our observations. In a prospective, randomized study 
conducted in women with hemorrhoidal disease and constipation 
following natural childbirth, supplementation with a probiotic Lacto-
bacillus casei strain afforded a significant improvement with regard to 
both abdominal and anal region symptoms compared to the placebo 
group (5). Two meta-analyses (6,7) assessing the impact of probiot-
ics on the functional constipation revealed their efficacy in regulat-
ing intestinal passage, frequency of defecation and stool consistency. 
However, the obtained effect depended on the probiotic strain being 
used in the study (Bifidobacterium lactis, Lactobacillus casei Shirota, 
Escherichia coli Nissle 1917, L. casei rhamnosus Lcr35, L. rhamno-
sus GG). In this study, also the Lactobacillus rhamnosus PL1 strain 
was shown to belong to the class of probiotics demonstrating effica-
cy in relieving the abdominal symptoms. The lack of significance in 
the frequency of constipation was probably due to the small number 
of subject in the study group. 
Despite the small number of subjects, significant improvement was 
observed in the group of patients treated for diverticulosis with re-
gard to the intensity of constipation as well as abdominal discom-
Tab.V.  Populations of the bacteria of genus Lactobacillus isolated from the stool 
samples collected from patients treated for hemorrhoidal disease. 
NO. V1 V2
TOTAL COUNT OF
 LACTOBACILLUS
 STRAINS (CFU/G OF 
STOOL)
INCLUDING THE 
TOTAL COUNT OF 
LACTOBACILLUS 
RHAMNOSUS PL1
STRAIN (CFU/G OF 
STOOL)
TOTAL COUNT OF
 LACTOBACILLUS 
STRAINS (CFU/G 
OF STOOL)
INCLUDING 
THE TOTAL 
COUNT OF 
LACTOBACILLUS 
RHAMNOSUS 
PL1
STRAIN (CFU/G 
OF STOOL)
1. 1.1 x 106 0 9.3 x 104 0
2. 2.0 x 105 0 3.8 x 106 6.3 x 103
3. 1.5 x 106 0 9.5 x 106 7.1 x 106
4. 0 0 4.8 x 107 4.8 x 107
5. 1.9 x 104 0 5.6 x 105 3.5 x 104
6. 9.7 x 105 0 1.4 x 106 2.0 x 105
7. 0 0 6.5 x 105 6.5 x 105
8. 1.3 x 108 0 9.5 x 104 4.7 x 102
9. 2.8 x 103 0 4.4 x 106 4.4 x 106
10. 1.2 x 104 0 1.1 x 106 1.1 x 106
11. 2.3 x 106 0 6.3 x 102 6.3 x 102
12. 0 0 9.1 x 105 9.1 x 105
13. 0 0 1.4 x 104 1.4 x 104
14. 8.1 x 106 0 1.3 x 105 1.3 x 105
15. 0 0 0 0
16. 0 0 7.7 x 105 7.7 x 105
17. 0 0 3.4 x 106 6.7 x 104
Tab. VI.  Populations of the bacteria of genus Lactobacillus isolated from the stool 
samples collected from patients treated for diverticulosis. 
NO. V1 V2
TOTAL COUNT OF
 LACTOBACILLUS 
STRAINS (CFU/G OF 
STOOL)
INCLUDING THE 
TOTAL COUNT OF 
LACTOBACILLUS 
RHAMNOSUS PL1
STRAIN (CFU/G OF 
STOOL)
TOTAL COUNT OF
 LACTOBACILLUS 
STRAINS (CFU/G 
OF STOOL)
INCLUDING THE 
TOTAL COUNT OF 
LACTOBACILLUS 
RHAMNOSUS PL1
STRAIN (CFU/G OF 
STOOL)
1. 5.9 x 107 0 1.1 x 104 7.3 x 103
2. 0 0 2.0 x 102 2.0 x 102
3. 0 0 6.0 x 106 6.0 x 105
4. 0 0 1.2 x 104 0
5. 0 0 6.1 x 105 6.1 x 105
6. 0 0 0 0
7. 0 0 6.78 x 105 0
Tab.IV. Intensity of clinical symptoms in patients with diverticulosis (mean ± SEM)
V1 V2 V4 P
Abdominal pain 2.28 ± 0.42 1.00 ± 0.36 0.83 ± 0.04 0.024
Flatulence 2.42 ± 0.42 1.17 ± 0.4 1.00 ± 0.25 0.029
Abdominal 
discomfort
2.85 ± 0.4 1.66 ± 0.21 1.00 ± 0.36 0.005
Sudden bowel 
movements
2 0 0 -
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in concentration of free ions of iron released upon decomposition 
of hemoglobin leads to an increase in the counts of Gram-negative 
bacteria of the family Enterobacteriaceae, particularly the bacilli of 
E. coli originating from the natural intestinal microflora (11). The 
persistence of the inflammation within the lower rectum and anus 
is due to the increase in the population of E. coli bacteria rather 
than to their special virulence (12). Such an increase in the E. coli 
counts was observed in most patients with hemorrhoidal disease 
in the baseline examination (SS1). 
In case of patients treated for diverticulosis, a correlation was ob-
served between the improvement in clinical parameters and the 
significant drop in the population of cocci of genus Enterococcus. 
It is known from the literature that Enterococcus faecalis may, to 
an extent similar to that of E. coli, induce the production of pro-in-
flammatory cytokines such as TNFα or IL-12p70 (13). Moreover, 
due to its peptidoglycan-containing cellular wall, Enterococcus fae-
calis is capable of initiating activation of TLR2-dependent nuclear 
factor κB within the immune cells, thus stimulating the immune 
system and consequently inducing inflammation. Thus, one may 
assume that the increased counts of E. faecalis within the intesti-
nal lumen and walls in the course of advanced inflammation con-
tribute to the persistence of this process (14). 
Extension of the standard treatment by additional supplementation 
using a probiotic product containing the Lactobacillus rhamnosus 
of diverticulosis. This makes probiotics an efficient component 
of the treatment of acute diverticulitis (8). Probiotics also play an 
important role in preventing the recurrence of the disease as well 
as in reducing the intensity of abdominal symptoms in patients 
with uncomplicated diverticulosis (10). In the study by Lamiki et 
al., probiotic strains of Lactobacillus acidophilus, L. heveticus, Bi-
fidobacterium spp. 420, and Lactobacillus paracasei significantly 
reduced abdominal symptoms in more than 70% of subjects. The 
analysis of stool samples collected from these patients revealed 
a statistically significant increase in the number of Lactobacil-
li and Bifidobacteriae during the supplementation period, and 
the genomic analysis confirmed the survival of the supplemented 
strains throughout the 6 month study period. 
Microbiological analysis performed by the authors revealed sig-
nificant changes in the composition of gut microbiota as early as 
3 weeks after the start of supplementation using a single probiotic 
strain Lactobacillus rhamnosus PL1. The changes varied depending 
on the underlying disease and disturbances caused by that disease 
in the bacterial composition of intestinal microflora. 
In the course of hemorrhoidal disease, occasional occurrence of 
blood in the rectal lumen is sufficient to disturb the microbiotic 
composition of the distal segment of the large intestine. Changes 
caused by the presence of blood may persist for long periods, even 
after successful treatment of the underlying disease. The increase 
Fig. 2.  Total counts of aerobic and anaeroobic bacteria in gut microbiota before (V1) and during (V2) supplementation with the probiotic L. rhamnosus PL1 strain: A) in patients treated 
for hemorrhoidal disease; and B) in patients treated for diverticulosis.
Fig. 3.   The mean population of the bacteria of geni Enterobacteriaceae (including E. coli) and Enterococcus (including E. faecalis) for: A) patients treated for hemorrhoidal disease; 
and B) patients treated for diverticulosis.
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efficacy of L. rhamnosus PL1 in the competition for receptors lo-
cated on the intestinal epithelial surface as compared to the cocci 
of genus Enterococcus. 
As early as after 3 weeks of probiotic supplementation, a two-fold 
increase in intestinal colonization with the bacteria of genus Lac-
tobacillus was observed in patients with hemorrhoidal disease 
as well as in the patients with diverticulosis. This effect is of par-
ticular value in the patient groups included in the study since the 
probiotic bacteria are directly responsible for the maintenance of 
correct microbial equilibrium within the gastrointestinal lumen. 
By reducing the pH of the intestinal lumen with their metabolites, 
they improve gastrointestinal motility and reduce the intensity of 
constipations.
To conclude, the probiotic  strain appears to be useful in restoring ap-
propriate ratios of bacterial populations in patients presenting with 
symptoms of proctitis in the course of the treatment of certain diseases 
of the lower gastrointestinal tract. However, further studies conducted 
in larger patient populations are required to dispel all doubts that may 
remain due to limited character of this study. 
PL1 strain significantly improved the clinical parameters of patients 
with the hemorrhoidal disease as well as patients with diverticulosis. 
The effect exerted by Lactobacillus on colonocytes may be man-
ifold, but it consists mainly in stimulation of mucus production, 
thus improving the function of the intestinal barrier (15). The in-
tegrity of the intestinal barrier may be improved by Lactobacillus 
strains also by means of increasing the mucosal levels of β-defen-
sin 2 (16). In addition, bacteria of genus Lactobacillus were shown 
to be capable of inhibiting cytokine-induced apoptosis of intesti-
nal wall cells (17). One may also assume that the bacteria of genus 
Lactobacillus, thanks to their synthesis of numerous antibacterial 
agents such as bacteriocins, lactic acid, acetic acid of pyroglutamic 
acid may actively reduce the populations of Gram-negative bacilli 
as observed in patients with hemorrhoidal disease as early as after 
3 weeks of supplementation.
In patients with diverticulosis, a decrease in the counts of cocci 
of genus Enterococcus was observed with simultaneous increase 
in the number of patients successfully colonized with the bacte-
ria of genus Lactobacillus which may be indicative of the higher 
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